UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 227

Sortiert nach

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

Journal of thoracic oncology, 2018-05, Vol.13 (5), p.682-688

2018

Link zum Volltext

Verfügbarkeit prüfen

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Science (American Association for the Advancement of Science), 2015-04, Vol.348 (6230), p.124-128

2015

Link zum Volltext

Verfügbarkeit prüfen

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153

Journal of clinical oncology, 2020-11, Vol.38 (33), p.3863-3873

2020

Link zum Volltext

Verfügbarkeit prüfen

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

JAMA : the journal of the American Medical Association, 2014-05, Vol.311 (19), p.1998

2014

Link zum Volltext

Verfügbarkeit prüfen

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Journal of thoracic oncology, 2020-06, Vol.15 (6), p.914-947

2020

Link zum Volltext

Verfügbarkeit prüfen

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement

American journal of respiratory and critical care medicine, 2019-09, Vol.200 (6), p.e31-e43

2019

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer

Scientific reports, 2018-02, Vol.8 (1), p.2592-10, Article 2592

2018

Link zum Volltext

Verfügbarkeit prüfen

Proteomic Analysis of Human Saliva From Lung Cancer Patients Using Two-Dimensional Difference Gel Electrophoresis and Mass Spectrometry

Molecular & cellular proteomics, 2012-02, Vol.11 (2), p.M111.012112-M111.012112, Article M111.012112

2012

Link zum Volltext

Verfügbarkeit prüfen

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

Cancer, 2016-03, Vol.122 (5), p.766-772

2016

Link zum Volltext

Verfügbarkeit prüfen

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Journal for immunotherapy of cancer, 2018-07, Vol.6 (1), p.75-75, Article 75

2018

Link zum Volltext

Verfügbarkeit prüfen

Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

Nature communications, 2021-07, Vol.12 (1), p.4172-4172, Article 4172

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

Frontiers in oncology, 2023-09, Vol.13, p.1247879-1247879

2023

Link zum Volltext

Verfügbarkeit prüfen

Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

Frontiers in immunology, 2020-06, Vol.11, p.1036-1036

2020

Link zum Volltext

Verfügbarkeit prüfen

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

Cancer science, 2020-12, Vol.111 (12), p.4510-4525

2020

Link zum Volltext

Verfügbarkeit prüfen

Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients

The New England journal of medicine, 2017-06, Vol.376 (25), p.2483-2485

Garon, Edward B

2017

Link zum Volltext

Verfügbarkeit prüfen

Characteristics of Lung Cancers Harboring NRAS Mutations

Clinical cancer research, 2013-05, Vol.19 (9), p.2584-2591

2013

Link zum Volltext

Verfügbarkeit prüfen

The Role of Interleukin 1β in the Pathogenesis of Lung Cancer

JTO clinical and research reports, 2020-03, Vol.1 (1), p.100001-100001, Article 100001

2020

Link zum Volltext

Verfügbarkeit prüfen

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients

Frontiers in oncology, 2020-10, Vol.10, p.572895-572895

2020

Link zum Volltext

Verfügbarkeit prüfen

A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment

Journal of thoracic oncology, 2018-09, Vol.13 (9), p.1284-1293

2018

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib plus Ramucirumab: The Best of Both Worlds?

Clinical cancer research, 2021-02, Vol.27 (4), p.905-907

Garon, Edward B

2021

Link zum Volltext

Verfügbarkeit prüfen

Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center

Cancer immunology research, 2018-03, Vol.6 (3), p.288-294

2018

Link zum Volltext

Verfügbarkeit prüfen

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

Cancer medicine (Malden, MA), 2022-01, Vol.11 (2), p.530-538

2022

Link zum Volltext

Verfügbarkeit prüfen

In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies

International journal of cancer, 2007-08, Vol.121 (3), p.675-682

2007

Link zum Volltext

Verfügbarkeit prüfen

The ascent of immune checkpoint inhibitors： is the understudy ready for a leading role

Cancer biology & medicine, 2017-11, Vol.14 (4), p.341-347

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 227

Suche als RSS-Feed

Aktive Filter

ThemaCarcinoma, Non-Small-Cell Lung - Pathology

KollektionElectronic Journals Library - Freely accessible e-journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(216)
Mit Volltextzugriff
(226)

Publikationsform

Artikel
(226)
Texte
(1)

Sprache

Englisch
(227)
Japanisch
(25)
Serbian
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Life Sciences & Biomedicine
(74)
Oncology
(68)
Humans
(54)
Respiratory System
(33)
Lung Neoplasms - Drug Therapy
(31)
Lung Cancer
(30)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(24)
Female
(24)
Male
(23)
Middle Aged
(21)
Aged
(20)
Immunotherapy
(19)
Adult
(18)
Mutation
(17)
Tumors
(15)
Aged, 80 And Over
(14)
Lung Neoplasms - Genetics
(14)
Cancer
(13)
Cancer Research
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations

Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer

Proteomic Analysis of Human Saliva From Lung Cancer Patients Using Two-Dimensional Difference Gel Electrophoresis and Mass Spectrometry

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY

Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients

Characteristics of Lung Cancers Harboring NRAS Mutations

The Role of Interleukin 1β in the Pathogenesis of Lung Cancer

Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients

A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment

Osimertinib plus Ramucirumab: The Best of Both Worlds?

Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center

Defining comprehensive biomarker‐related testing and treatment practices for advanced non‐small‐cell lung cancer: Results of a survey of U.S. oncologists

In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies

The ascent of immune checkpoint inhibitors： is the understudy ready for a leading role

Aktive Filter

Suchergebnisse filtern